Skip to main content
Contact Us
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
CDMO Intelligence
Real World Data
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Immuron
Evaluate
February 19, 2021
Immunome soars 76% on Covid-19 hopes – but that's nothing
June 12, 2018
Investors toast Galmed Nash results, but what will the FDA say?
February 13, 2017
Intercept strikes at the heart of the Nash problem
July 25, 2016
Despite a deck stacked in its favour, Tobira fails in NASH
May 03, 2016
Therapy focus – NASH projects set for data in dog days of summer
September 24, 2015
Conatus makes a splash in NASH
April 08, 2015
Astra first big pharma to dip toe in simmering NASH waters
March 10, 2015
NASH craze lives on, despite the unknowns
August 09, 2013
Sanofi brings prospect of C difficile vaccine closer
Latest Reports
July 27, 2023
H1 Round Up: The haves and the have-nots
July 21, 2023
ADA/EASL eBook
Editor's Picks
July 03, 2023
Astrazeneca and Daiichi’s big reveal disappoints
July 13, 2023
Pharma finds a way to gain weight
July 03, 2023
Protagonist investors flake as psoriasis pill disappoints
June 29, 2023
Approaching datasets for big pharma
June 27, 2023
Nkarta goes back to basics